India's Vaccine Manufacturing Revolution: A Path to Safety and Transparency

India should focus on enhancing local vaccine manufacturing and research for better control over safety, according to GTRI. They also suggest investigating adverse health events post-vaccination to improve transparency and safety. These actions are vital in light of global debates sparked by "The Pfizer Papers."

In a call for action, India's Global Trade Research Initiative (GTRI) emphasized the need to scale up local vaccine manufacturing and research. The think tank believes that this move is crucial for India to gain better control over the safety of pharmaceutical products.

GTRI also urged the government to initiate investigations into all adverse health events following vaccinations. This step could contribute to more transparent, safe, and effective future vaccine rollouts, aligning with international standards and public health priorities.

The suggestions come amidst the ongoing global discourse incited by the October 2024 release of "The Pfizer Papers: Crimes Against Humanity," which has challenged vaccine safety, ethics, and transparency worldwide. Ajay Srivastava, GTRI Founder, highlighted the necessity of prioritizing public health over profit as future pandemic responses are developed.

(With inputs from agencies.)